ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • exercise and rehabilitation
  • exercise and rheabilitation
  • exercise and rheumatoid arthritis (RA)
  • exercise and steroids
  • Exercise and systemic sclerosis
  • exercise and takayasu arteritis
  • exon 2 and fmf
  • Experimental Arthritis
  • extra pulmonary sarcoidosis
  • extra-synovial
  • extraarticular manifestations
  • extraarticular manifestations and juvenile idiopathic arthritis (JIA)
  • extraarticular manifestations and outcome measures
  • extraarticular manifestations and psoriatic arthritis
  • extraarticular manifestations and respiratory disease
  • extraarticular manifestations and rheumatoid arthritis (RA)
  • extraarticular manifestations and spondylarthritis
  • extracellular matrix proteins
  • extracellular matrix proteins and integrins
  • extracellular matrix proteins and kinase
  • extracellular matrix proteins and osteoarthritis
  • Extracellular matrix proteins and rheumatoid arthritis
  • Extracellular matrix proteins and systemic sclerosis
  • extracellular matrix proteins and type II collagen
  • extracellular vesicles
  • Extracorporeal shockwave therapy
  • Extraglandular manifestation
  • extravesicular microRNA and seronegative rheumatoid arthritis
  • Eye disease
  • eye disease and hydroxychloroquine
  • eye disease and systemic lupus erythematosus (SLE)
  • eye disease and uveitis
  • eye disease and vasculitis
  • Eye Disorders
  • EZH2
  • FACIT-Fatigue
  • factor XIII
  • Faecal Incontinence
  • FAERS
  • FAI
  • Fall Risk
  • Fall Risk and foot
  • Fall Risk and fracture risk
  • Fall Risk and orthopaedic
  • Fall Risk and osteoarthritis
  • Fall Risk and rheumatoid arthritis (RA)
  • Falls
  • Familial Mediterranean fever
  • familial Mediterranean fever and Blau syndrome
  • Familial Mediterranean fever and fertility
  • familial Mediterranean fever and genetic disorders
  • familial Mediterranean fever and genetics
  • Familial Mediterranean fever and heart disease
  • familial Mediterranean fever and inflammation
  • Familial Mediterranean fever and interleukins (IL)
  • Familial Mediterranean fever and intima medial thickness
  • familial Mediterranean fever and laboratory tests
  • familial Mediterranean fever and outcome measures
  • familial Mediterranean fever and pediatric rheumatology
  • familial Mediterranean fever and pediatrics
  • familial Mediterranean fever and pregnancy
  • familial Mediterranean fever and quality of life
  • familial Mediterranean fever and tocilizumab
  • familial Mediterranean fever and treatment
  • familial Mediterranean fever and treatment options
  • Familial Mediterrenean Fever
  • Family History
  • family planning
  • family planning and Reproductive Health
  • family studies
  • family studies and fibromyalgia
  • family studies and genetics
  • Family studies and gout
  • family studies and osteoprotegerin
  • family studies and population studies
  • family studies and questionnaires
  • Family studies and rheumatoid arthritis
  • family studies and risk assessment
  • family studies and spondylarthritis
  • Family studies and systemic lupus erythematosus (SLE)
  • family studies and vasculitis
  • Farber disease
  • fas ligand
  • fast track
  • Fast Track Clinic
  • fat
  • Fatal anemia
  • Fatigue
  • fatigue and cognitive dysfunction
  • fatigue and das
  • fatigue and depression
  • fatigue and Early Rheumatoid Arthritis
  • fatigue and fibromyalgia
  • fatigue and functional status
  • fatigue and interdisplinary
  • fatigue and interferons
  • fatigue and juvenile SLE
  • fatigue and mitochondrial myopathy
  • fatigue and mobile
  • fatigue and obesity
  • fatigue and pain
  • fatigue and patient outcomes
  • fatigue and psoriatic arthritis
  • fatigue and quality of life
  • fatigue and remission
  • Fatigue and rheumatoid arthritis (RA)
  • Fatigue and self-management
  • Fatigue and spondylarthritis
  • fatigue and systemic lupus erythematosus (SLE)
  • Fatty liver
  • Fc receptors
  • Fc receptors and kinase
  • Fc receptors and rheumatoid arthritis (RA)
  • Fc receptors and vasculitis
  • FDA
  • FDA and colchicine
  • FDG-PET
  • FDG-PET/CT
  • feasibility
  • features
  • Febuxostat
  • febuxostat and gout
  • Febuxostat and hyperuricemia
  • febuxostat and meta-analysis
  • fellow
  • Fellow-In-Training
  • Fellow-In-Training and educational research
  • Fellow-In-Training and fellowship programs
  • Fellow-In-Training and trainee
  • fellowship
  • fellowship programs
  • fellowship programs and faculty development
  • fellowship programs and medical education
  • fellowship programs and musculoskeletal sonography
  • fellowship programs and pediatric rheumatology
  • fellowship programs and rehabilitation
  • Fellowship programs and ultrasonography
  • fellowship programs and ultrasound
  • female and predictors
  • femur bone shape
  • Femur Fractures
  • Fertility
  • fertility and pediatric rheumatology
  • fertility and pregnancy
  • fetal development
  • Fever
  • fever and genetics
  • fever and gout
  • fever and innate immunity
  • fever and nod-like receptor (NLR)
  • Fever and pediatric rheumatology
  • fever and treatment
  • Fever and tumor necrosis factor (TNF)
  • fever and ulcers
  • fHLH
  • fibroblast-ilke synoviocytes and somatic mutations
  • fibroblast-like synoviocytes
  • Fibroblasts
  • fibroblasts and glucocorticoids
  • fibroblasts and inflammation
  • Fibroblasts and inflammatory arthritis
  • fibroblasts and juvenile arthritis
  • fibroblasts and leukocytes
  • Fibroblasts and mast cells
  • fibroblasts and matrix metalloproteinase (MMP)
  • fibroblasts and mesenchymal stem cells
  • fibroblasts and monocytes
  • fibroblasts and osteoclastogenesis
  • fibroblasts and pathogenesis
  • fibroblasts and rheumatic disease
  • fibroblasts and rheumatoid arthritis
  • fibroblasts and rheumatoid arthritis (RA)
  • fibroblasts and scleroderma
  • fibroblasts and sex hormones
  • fibroblasts and signal transduction
  • fibroblasts and skin
  • fibroblasts and synovial cells
  • Fibroblasts and synovium
  • fibroblasts and systemic sclerosis
  • fibroblasts and tofacitinib
  • fibroblasts and transcription factor
  • fibroblasts and transforming growth factor
  • fibroblasts and treatment
  • Fibroblasts and vasculitis
  • Fibroblasts, Dermal
  • Fibroblasts, Other
  • Fibroblasts, Synovial
  • fibromyalgia
  • fibromyalgia and abuse
  • fibromyalgia and diagnostic criteria
  • fibromyalgia and Disease Activity
  • fibromyalgia and exercise
  • fibromyalgia and functional status
  • fibromyalgia and funding
  • Fibromyalgia and genetics
  • fibromyalgia and genomics
  • fibromyalgia and guidelines
  • fibromyalgia and health care cost
  • fibromyalgia and hypermobility
  • Fibromyalgia and imaging techniques
  • First |
  • « Previous Page
  • 17
  • 18
  • 19
  • 20
  • 21
  • [22]
  • 23
  • 24
  • 25
  • 26
  • 27
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology